FDA Conducting Safety Study of Abortion Pill Mifepristone Amid Pro-Life Pressure
The FDA is conducting a real-world safety study of the abortion pill mifepristone that includes data from online sales, following promises made during Trump administration confirmation hearings. Pro-life advocates have pressured the administration to restrict online access to the pill, citing a report claiming 11% of women experienced serious adverse events from at-home abortions. Anti-abortion groups say the study timeline—expected to take at least six more months—is insufficient and are pushing for additional restrictions through the Department of Justice.
The FDA has confirmed it is conducting a comprehensive safety study of mifepristone, the abortion pill, incorporating data from online sales following Biden-era changes that eliminated in-person screening requirements. Health and Human Services Secretary Robert F. Kennedy Jr. and former FDA Commissioner Marty Makary promised during confirmation hearings to undertake this study. Pro-life advocates cite an Ethics and Public Policy Center report suggesting approximately 11% of women experienced serious adverse events from at-home abortions, though this figure comes from insurance claims data. Anti-abortion groups have grown frustrated with delays in the study and are skeptical that the expected six-month timeline will lead to action before the 2026 midterm elections. Beyond the FDA study, pro-life leaders are urging the Trump administration's Department of Justice to settle a lawsuit with Louisiana and support state-level restrictions on online abortion pill sales.
What's missing
The article does not provide independent verification of the 11% adverse events figure cited from the Ethics and Public Policy Center report, nor does it include FDA's own assessment of mifepristone's safety profile or responses from medical organizations regarding the safety claims. The study's methodology, sample size, and timeline for completion are not detailed.
What different sources said
- Washington ExaminerRight
Pro-life activists skeptical of FDA abortion pill study
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.